| Literature DB >> 36002895 |
David Brain1, Amarzaya Jadambaa1, Sanjeewa Kularatna2.
Abstract
BACKGROUND: While involving users in healthcare decision-making has become increasingly common and important, there is a lack of knowledge about how to best design community-based health screening programs. Reviews of methods that incorporate discrete choice experiments (DCEs) are scarce, particularly for non-cancer illnesses like cardiovascular disease, diabetes and liver disease. We provide an overview of currently available applications and methods available by using DCEs in health screening programs, for chronic conditions.Entities:
Keywords: Chronic disease; Community screening program; Discrete choice experiment; Preferences
Mesh:
Year: 2022 PMID: 36002895 PMCID: PMC9400308 DOI: 10.1186/s12913-022-08464-7
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.908
Fig. 1PRISMA flow diagram showing process of study selection for inclusion in review
DCE background information on the 27 included studies
| Item | Specification | Number of studies |
|---|---|---|
| Country of origin | Europe | 16 |
| US | 5 | |
| Australia | 4 | |
| Asia | 2 | |
| Screening program of interest | Cancer screening programa | 26 |
| Cardiovascular disease screening program | 1 | |
| Target population | General public | 21 |
| Healthcare provider | 5 | |
| Healthcare provider and stakeholder | 1 | |
| Main objective | Consumer preference | 21 |
| Health professionals’ preferences | 6 | |
| Sample size calculation reported | Yes | 18 |
| No | 9 | |
| Ethical approval | Approved by international organisation | 2 |
| Approved by local organisation | 16 | |
| Not required | 1 | |
| Not reported | 8 | |
| Administration of survey | Self-completed (online) | 13 |
| Self-completed (paper based) | 7 | |
| Self-completed (paper based/online) | 3 | |
| Face to face interview | 4 | |
| How participants were recruited | Via an online survey panel | 12 |
| Via an online survey panel/snowball | 1 | |
| Via email | 1 | |
| Via mail | 4 | |
| Via email/mail | 2 | |
| Directly invited | 5 | |
| Not clearly reported | 2 | |
| Reimbursements | Money | 8 |
| Gift | 1 | |
| Voucher | 1 | |
| Not reported | 17 |
aColorectal, breast, cervical, prostate, oesophageal, lung, skin cancer screening programmes
Developing choice sets
| Item | Specification | Number of studies |
|---|---|---|
| Methods for attributes and levels selection | Literature review, expert’s opinion | 3 |
| Literature review, expert’s opinion, qualitative worka | 3 | |
| Literature review, expert’s opinion, existing data | 2 | |
| Literature review, expert’s opinion, existing research | 1 | |
| Literature review, qualitative worka | 10 | |
| Literature review, existing research | 2 | |
| Literature review, existing data | 1 | |
| Qualitative work only | 2 | |
| Based on existing research | 3 | |
| Pilot testing | Yes | 18 |
| No | 1 | |
| Not reported | 8 | |
| Number of attributes | 3 | 1 |
| 4 | 4 | |
| 5 | 10 | |
| 6 | 6 | |
| 7 or more | 6 | |
| Average number of attributes | 5 to 6 | |
| Attributes coverede | Procedure attributes | 26 |
| Cost attributes | 18 | |
| Outcome attributes | 14 | |
| Other | 7 | |
| Number of levels | 2 to 3 | 13b |
| 2 to 4 | 6c | |
| 2 to 5 | 5d | |
| 3 to 4 | 2 | |
| 4 to 6 | 1 | |
| Labelling | Generic | 16 |
| Labelled | 6 | |
| Both | 1 | |
| Not clearly reported | 4 | |
| Number of alternatives (not including opt-out option) | 1 | 2 |
| 2 | 20 | |
| 3 | 4 | |
| 4 or more | 1 | |
| Opt-out option | Yes | 15 |
| No | 12 |
aQualitative work: Interview with experts and/or stakeholders and/or healthcare providers and/or target population; and/or focus group; and or secondary analysis of qualitative data; b Includes 2 and 3; c includes 4; d includes 5; e Total more than 27 as each study may use many attributes
Experimental design of included studies
| Design aspect | Specification | Number of studies |
|---|---|---|
| Design type | Fractional factorial | 25 |
| Full factorial | 2 | |
| Fractional factorial type | Orthogonal | 6 |
| Balanced | 2 | |
| Both | 1 | |
| NA | 2 | |
| Not stated | 16 | |
| Design plan | Main effects plus two-way interactions | 5 |
| Main effects only | 2 | |
| Not clearly reported but main effects only in analysis | 15 | |
| Not reported and unclear from analysis | 5 | |
| Measures to select design | D-efficiency | 16 |
| C-efficiency | 1 | |
| Not stated | 10 | |
| Design software | Ngene | 8 |
| SAS | 6 | |
| Sawtooth | 5 | |
| SPSS | 2 | |
| Not specified | 6 | |
| Blocking | Yes | 11 |
| No | 14 | |
| Not sure/unclear | 2 | |
| Number of choices per respondent | 1–5 | 1 |
| 6–10 | 5 | |
| 10–15 | 13 | |
| 16–20 | 6 | |
| 21 or more | 2 |
Econometric analyses of included studies
| Analytic aspect | Specification | Number of studies |
|---|---|---|
| Econometric analysis model | Mixed logit/random parameter logit | 6 |
| Hierarchical Bayes mixed logit HB-MXL | 4 | |
| Multinominal logit MNL | 3 | |
| Latent class logit | 3 | |
| Mixed Multinominal logit MMNL | 1 | |
| Logit | 2 | |
| Random effect probit | 1 | |
| Random parameter logit | 1 | |
| Generalised multinomial - GMNL | 1 | |
| Four models: MNL, Heteroskedastic multinomial – HMNL, HMNL + systematic preference heterogeneity, HMNL + systematic preference heterogeneity + random opt out utility | 1 | |
| Two models: MNL/conditional logit, Multinomial probit MNP | 1 | |
| Two models: MNL/conditional logit, mixed logit | 1 | |
| Two models: MNL/conditional logit, Latent class logit | 1 | |
| Not clearly reported | 1 | |
| Software for econometric analysis | STATA | 6 |
| Nlogit | 5 | |
| Sawtooth | 3 | |
| SPSS | 3 | |
| R | 2 | |
| SAS | 2 | |
| Pythonbiogeme | 1 | |
| Not specified | 5 |
Presented outcome measures of included studies
| Item | Specification | Number of studies |
|---|---|---|
| Presented outcome measurea | Utility score |
|
| Willingness to pay |
| |
| Willingness to accept |
| |
| Relative importance and ranking |
| |
| Uptake rates change according to change in attributes/levels |
| |
| Part-worth utility score |
| |
| Relative risk |
| |
| Choice shares |
| |
| Maximum acceptable risk |
|
a Total more than 27 as two or more outcomes were presented in one study